Adenylate Kinase Dynamics in Energy Metabolism

Adenylate kinase (AK) is a ubiquitous phosphotransfer enzyme that catalyses the reversible reaction ATP + AMP ⇌ 2 ADP, thereby underpinning cellular energy homeostasis across compartments. Multiple AK isozymes are distributed between cytosol, mitochondria and specialised organelles, where they monitor and regulate adenine nucleotide ratios to match energy supply with demand. Beyond simple phosphoryl transfer, AK acts as a metabolic sensor: changes in local AMP and ADP levels trigger downstream signalling pathways, notably the AMP–activated protein kinase (AMPK) axis, which coordinates processes from mitochondrial biogenesis to autophagy. Dynamic assembly and localisation of AK isoforms ensure rapid energy transfer in high-demand locales such as muscle fibres, synapses and cell motility structures. Perturbations in AK expression or function have been linked to immunodeficiencies, cardiac dysfunction, metabolic syndromes and tumour progression. Recent advances have illuminated how AK-driven nucleotide flux interfaces with metabolic reprogramming in cancer, stress adaptation under hypoxia and the fine-tuning of circadian rhythms. Elucidating the spatio-temporal dynamics of AK activity promises new routes to therapeutic modulation of energy metabolism in a range of diseases.

Research from Nature Portfolio

Recent studies have uncovered a critical role for a nucleocytosolic AK variant in promoting cancer stem cell traits. Overexpression of this AK homologue in colorectal carcinoma was shown to facilitate phosphorylation of a key glycolytic enzyme, thereby enhancing the Warburg effect, lowering reactive oxygen species and driving invasion, self-renewal and chemoresistance. Depletion of this AK variant impaired tumour initiation and reversed mesenchymal markers, pointing to its promise as a drug target to disrupt metabolic advantage in aggressive malignancies.

Investigations into adenylate kinase 2 (AK2) in lung adenocarcinoma have revealed its dual function in energy metabolism and autophagy. Elevated AK2 expression correlated with poor patient survival and enhanced tumour cell proliferation, migration and invasion. Genetic silencing of AK2 not only suppressed tumour growth in vitro and in xenograft models but also synergised with autophagy inhibition to induce apoptosis. These findings highlight AK2 as both a prognostic marker and therapeutic entry point in lung cancer.

Adenylate Kinase Dynamics in Energy Metabolism publication trend

The graph below shows the total number of articles in adenylate kinase dynamics in energy metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Adenylate kinase: Enzyme catalysing the reversible transfer of a phosphate group between adenine nucleotides (ATP + AMP ⇌ 2 ADP).

Isozyme: Distinct enzyme variant with similar catalytic activity but differing in sequence, regulation or subcellular localisation.

Phosphotransfer: Transfer of a phosphate group from one molecule to another, essential for cellular energy transactions.

AMP–activated protein kinase (AMPK): Cellular energy sensor activated by rising AMP/ATP ratio that orchestrates metabolic adaptation.

Metabolic reprogramming: Adaptive alteration of metabolic pathways to meet specific biosynthetic or energetic demands, often seen in cancer.

Warburg effect: Tendency of proliferating cells to favour glycolysis over oxidative phosphorylation even under aerobic conditions.

References

1. Regulation of Adenine Nucleotide Metabolism by Adenylate Kinase Isozymes: Physiological Roles and Diseases. International Journal of Molecular Sciences (2023).
2. Adenylate Kinase and Metabolic Signaling in Cancer Cells. Frontiers in Oncology (2020).
3. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. Nature Communications (2017).
4. Modulation of Cell Motility by Spatial Repositioning of Enzymatic ATP/ADP Exchange Capacity*. Journal of Biological Chemistry (2008).
5. Prognostic and therapeutic potential of Adenylate kinase 2 in lung adenocarcinoma. Scientific Reports (2019).